Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of Hepatic Sarcoidosis.
Sollors J, Schlevogt B, Schmidt HJ, Woerns MA, Galle PR, Qian Y, Antoni C, Weis CA, Hetjens S, Bergner R, Ebert MP, Teufel A. Sollors J, et al. Among authors: woerns ma. J Gastrointestin Liver Dis. 2022 Sep 15;31(3):323-330. doi: 10.15403/jgld-4122. J Gastrointestin Liver Dis. 2022. PMID: 36112714 Free article.
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M; Working Group of Internal Oncology. Moehler M, et al. Eur J Cancer. 2014 Dec;50(18):3125-35. doi: 10.1016/j.ejca.2014.09.013. Epub 2014 Oct 15. Eur J Cancer. 2014. PMID: 25446376 Free article. Clinical Trial.
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Moehler M, et al. BMC Cancer. 2019 Jan 11;19(1):55. doi: 10.1186/s12885-018-5223-7. BMC Cancer. 2019. PMID: 30634942 Free PMC article. Clinical Trial.
Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
Moehler M, Thomaidis T, Zeifri C, Barhoom T, Marquardt J, Ploch P, Schattenberg J, Maderer A, Schimanski CC, Weinmann A, Woerns MA, Kranich AL, Warnecke JM, Galle PR. Moehler M, et al. Among authors: woerns ma. J Cancer Res Clin Oncol. 2015 Mar;141(3):515-22. doi: 10.1007/s00432-014-1829-6. Epub 2014 Sep 19. J Cancer Res Clin Oncol. 2015. PMID: 25230900
Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort.
Vollmar J, Stern F, Lackner K, Mildenberger P, Greif-Higer G, Mittler J, Darstein F, Foerster F, Grimm D, Marquardt JU, Schattenberg J, Woerns MA, Lang H, Galle PR, Zimmermann T. Vollmar J, et al. Among authors: woerns ma. Z Gastroenterol. 2020 Jan;58(1):30-38. doi: 10.1055/a-1008-9736. Epub 2020 Jan 13. Z Gastroenterol. 2020. PMID: 31931538 English.
Midterm follow-up after DC-BEAD™-TACE of hepatocellular carcinoma (HCC).
Skowasch M, Schneider J, Otto G, Weinmann A, Woerns MA, Dueber C, Pitton MB. Skowasch M, et al. Among authors: woerns ma. Eur J Radiol. 2012 Dec;81(12):3857-61. doi: 10.1016/j.ejrad.2012.07.002. Epub 2012 Jul 25. Eur J Radiol. 2012. PMID: 22840383 Clinical Trial.